Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

807
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
807

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Emre Karabay's Letter to the Editor re: Ritter Manuel, Stein Johannes, Barber Neil, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. Eur Urol Focus 2026;12:266-74.

European urology focus·2026
Same author

Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Modelling kidney cystogenesis using human kidney tubuloid cultures.

BMC molecular and cell biology·2026
Same author

Effects of regular consumption of a β-glucan-rich oyster mushroom powder on cholesterol metabolism in adults with moderately elevated LDL-cholesterol concentrations: a double-blind randomized controlled trial.

Nutrition & metabolism·2026
Same author

Quantifying the Renal Impact of [<sup>177</sup>Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Combined elevation of pre-treatment γ-glutamyltransferase and lactate dehydrogenase as independent prognosticator for metastatic renal cell carcinoma undergoing immune-based therapy.

Scientific reports·2026
Same journal

Notice of Retraction. Ren Y, et al. Personality Traits and Social Isolation in Older Adults. JAMA Netw Open. 2026;9(5):e269569.

JAMA network open·2026
Same journal

Error in Grant Number in Funding/Support Section.

JAMA network open·2026
Same journal

The Supplementary Role of Friends in Caregiving Networks.

JAMA network open·2026
Same journal

Urbanicity, Neighborhood Conditions, and Dementia Mortality.

JAMA network open·2026
Same journal

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

JAMA network open·2026
Same journal

Limbic System Microstructure in Neonates With Antenatal Opioid Exposure.

JAMA network open·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

Thomas Büttner1, Niklas Klümper1, Jörg Ellinger1

  • 1Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.

JAMA Network Open
|March 6, 2026
PubMed
Summary
This summary is machine-generated.

The Bellmunt Risk Score (BRS) effectively predicts survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This validated prognostic tool aids in treatment decisions and patient discussions for mCRPC management.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

975
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.6K

Related Experiment Videos

Last Updated: Mar 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

975
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.6K

Area of Science:

  • Oncology
  • Prognostic Biomarkers
  • Clinical Trial Analysis

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents a variable clinical course, requiring effective prognostic tools for personalized patient management.
  • Accurate prediction of survival is crucial for guiding treatment strategies in mCRPC.

Purpose of the Study:

  • To validate the prognostic ability of the Bellmunt Risk Score (BRS) in predicting overall survival (OS) and radiographic progression-free survival in patients with mCRPC.
  • To assess the BRS's utility across different treatment settings in mCRPC.

Main Methods:

  • Post hoc analysis of two international, multicenter, phase 3 randomized clinical trials (ACIS and ELM-PC-5) involving 1756 patients with mCRPC.
  • The Bellmunt Risk Score (BRS) was calculated based on Eastern Cooperative Oncology Group Performance Status, hemoglobin level, and presence of liver metastases.
  • Overall survival (OS) and radiographic progression-free survival were analyzed using Kaplan-Meier and multivariable Cox proportional hazards regression.

Main Results:

  • A higher BRS was consistently associated with unfavorable OS in both trial cohorts.
  • In the ACIS trial, median OS decreased from 42.2 months (BRS=0) to 9.1 months (BRS=3), with adjusted hazard ratios (AHRs) for OS ranging from 1.37 to 8.29.
  • In the ELM-PC-5 trial, median OS decreased from 23.0 months (BRS=0) to 3.2 months (BRS=3), with AHRs for OS ranging from 1.65 to 4.43.
  • The BRS demonstrated robustness as an independent prognostic factor for both OS and radiographic progression-free survival.

Conclusions:

  • The Bellmunt Risk Score (BRS) is a validated prognostic tool for patients with mCRPC, providing clinically meaningful information across various treatment lines.
  • The simplicity of the BRS makes it a practical aid for guiding treatment decisions and facilitating prognostic discussions in routine clinical practice.
  • The BRS enhances individualized patient management in mCRPC by offering reliable survival predictions.